CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has been assigned a consensus recommendation of “Hold” from the nineteen research firms that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $76.67.
Several research firms have recently commented on CRSP. Cantor Fitzgerald reissued a “neutral” rating on shares of CRISPR Therapeutics in a report on Thursday, May 9th. Needham & Company LLC reaffirmed a “buy” rating and issued a $88.00 price objective on shares of CRISPR Therapeutics in a research note on Thursday, June 27th. JMP Securities reaffirmed a “market outperform” rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a research note on Thursday, May 9th. Piper Sandler reaffirmed an “overweight” rating and issued a $105.00 price objective on shares of CRISPR Therapeutics in a research note on Monday, June 17th. Finally, Citigroup dropped their price objective on CRISPR Therapeutics from $89.00 to $84.00 and set a “buy” rating for the company in a research note on Thursday, May 23rd.
Check Out Our Latest Stock Analysis on CRISPR Therapeutics
Insider Activity
Hedge Funds Weigh In On CRISPR Therapeutics
Several institutional investors have recently added to or reduced their stakes in the business. Riggs Asset Managment Co. Inc. increased its stake in CRISPR Therapeutics by 66.7% in the first quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock valued at $34,000 after purchasing an additional 200 shares during the last quarter. Orion Capital Management LLC increased its holdings in shares of CRISPR Therapeutics by 44.0% during the 1st quarter. Orion Capital Management LLC now owns 720 shares of the company’s stock worth $49,000 after buying an additional 220 shares during the last quarter. National Bank of Canada FI raised its position in shares of CRISPR Therapeutics by 35.0% in the 2nd quarter. National Bank of Canada FI now owns 848 shares of the company’s stock worth $46,000 after buying an additional 220 shares during the period. Larson Financial Group LLC boosted its holdings in CRISPR Therapeutics by 95.5% in the second quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock valued at $31,000 after acquiring an additional 276 shares during the last quarter. Finally, Wealthcare Advisory Partners LLC grew its position in CRISPR Therapeutics by 7.7% during the first quarter. Wealthcare Advisory Partners LLC now owns 4,200 shares of the company’s stock valued at $286,000 after acquiring an additional 300 shares during the period. 69.20% of the stock is currently owned by institutional investors and hedge funds.
CRISPR Therapeutics Price Performance
CRSP opened at $51.11 on Wednesday. The business has a 50 day simple moving average of $57.20 and a 200-day simple moving average of $63.27. The stock has a market capitalization of $4.34 billion, a P/E ratio of -18.79 and a beta of 1.70. CRISPR Therapeutics has a 12 month low of $37.55 and a 12 month high of $91.10.
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.08). The firm had revenue of $0.50 million during the quarter, compared to analyst estimates of $25.53 million. CRISPR Therapeutics’s revenue for the quarter was down 99.5% on a year-over-year basis. During the same period in the prior year, the company earned ($0.67) earnings per share. Research analysts anticipate that CRISPR Therapeutics will post -5.52 EPS for the current year.
About CRISPR Therapeutics
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Read More
- Five stocks we like better than CRISPR Therapeutics
- How to Calculate Options Profits
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- About the Markup Calculator
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- EV Stocks and How to Profit from Them
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.